SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Dr. Reddy's Laboratories informs about press release

04 Sep 2021 Evaluate

Dr. Reddy's Laboratories has informed that it enclosed a Press Release on 4th September titled ‘Dr. Reddy's Laboratories enters into definitive agreement with Citius Pharmaceuticals, Inc. to sell its rights to anti-cancer agent E7777 (denileukin diftitox)’.

The above information is a part of company’s filings submitted to BSE.


Dr. Reddys Labs. Share Price

1363.50 -12.80 (-0.93%)
30-Jun-2026 12:53 View Price Chart
Peers
Company Name CMP
Sun Pharma. Inds. 1868.45
Dr. Reddys Labs. 1363.50
Cipla 1474.25
Zydus Lifesciences 1122.20
Lupin 2410.00
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through: